Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) announced today the signature of a memorandum of understanding laying the foundation for a strategic alliance with the Salk Institute for Biological Studies (La Jolla, California, USA).

“We are delighted to have the opportunity to work with sanofi-aventis to support our researchers and promote scientific exchange with an ultimate goal of improving human health,” stated Dr. Marsha Chandler, Executive Vice President of the Salk Institute.

Designed as a close research collaboration, the “Sanofi-aventis Regenerative Medicine Program” at the Salk Institute will support the Institute’s stem cell facility, for up to five years, and provide flexible financial support to individual scientists to accelerate innovative research projects in public health. Further, it will complement the Salk Institute’s efforts to promote scientific discoveries that have an important impact on the understanding of human health.

“This strategic alliance will significantly enrich our research activities in the field of regenerative medicine and will give us the opportunity to apply the discoveries to potential new diagnostics or therapies for human diseases,” underlined Dr. Marc Cluzel, Senior Vice President, Research & Development, sanofi-aventis.

About the Salk Institute for Biological Studies

The Salk Institute for Biological Studies in La Jolla, California, is an independent non-profit organization dedicated to fundamental discoveries in the life sciences, the improvement of human health and the training of future generations of researchers. Jonas Salk, M.D., whose polio vaccine all but eradicated the crippling disease poliomyelitis in 1955, opened the Institute in 1965 with a gift of land from the City of San Diego and the financial support of the March of Dimes.
For more information, please connect to: www.salk.edu/faculty/technology_transfer.html.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY).

Related posts:

1. French BioBeach facilitates a strategic alliance between Sanofi-Aventis and the Salk Institute
2. Eight French Research Organisations Create The National Alliance for Life and Health Sciences
3. SD News: Sanofi-aventis To Acquire TargeGen, Inc.
4. Salk receives $6.6M grant
5. Sanofi to buy U.S. group Chattem for $1.9 billion